NI-2801
HER2-positive solid tumors
PreclinicalActive
Key Facts
About Light Chain Bioscience
Light Chain Bioscience is a private, clinical-stage biotech advancing a pipeline of bispecific antibodies using its proprietary Kλ body technology. Its lead programs target CD47 in a tumor-restricted manner to overcome historical safety challenges, with one asset in Phase II and several others in Phase I/II development. The company operates a partnership-driven business model, co-developing assets with partners like LamKap Bio, and is positioned in the competitive but high-potential bispecific antibody and CD47-targeting therapeutic space.
View full company profileTherapeutic Areas
Other HER2-positive solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CT-0525 | Carisma Therapeutics | Preclinical |
| Emi-Le (XMT-2056) | Day One Biopharmaceuticals | Phase 1 |